Litcius/Paper detail

Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway

Boshen Yang, Taixi Li, Zhixiang Wang, Yuankang Zhu, Kaifan Niu, Sien Hu, Zhiqi Lin, Xinjie Zheng, Xian Jin, Chengxing Shen

2024International Journal of Biological Sciences43 citationsDOIOpen Access PDF

Abstract

This study highlighted the potential significance of cellular senescence in SCM pathogenesis and suggested Rux-based senomorphic therapy as a promising therapeutic approach for SCM.

Topics & Concepts

RuxolitinibCardiomyopathyMedicineSignal transductionSTAT3SenescencePharmacologyCancer researchInternal medicineCardiologyHeart failureCell biologyBiologyBone marrowMyelofibrosisSignaling Pathways in DiseaseCardiac Fibrosis and RemodelingAcute Myeloid Leukemia Research
Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway | Litcius